Personalization And Digital Are Pushing IVDs Onto The Health Care High Ground
Investment in advanced in vitro diagnostics is increasing as the technologies themselves are becoming less esoteric and more easily "understood" by patients and providers alike. Are these technologies finally breaking through the glass ceiling to visibly assume their rightful place in health care delivery?
You may also be interested in...
Diagnostics should be funded in a way that recognizes the value they bring. The UK IVD industry should also have a seat on the newly-formed Life Sciences Council. These are just two changes that would help diagnostics break through the adoption barrier in the UK and help the health-care system save "billions," say manufacturers.
The health products industry, methods of care delivery and even the public's expectations for improved tools to prevent, monitor and treat disease have transformed dramatically in the past five years. The changes anticipated over a similar period ahead are potentially even more marked, with business continuity impacts for medtech and pharma concerns, according to Deloitte LLP experts who were on the circuit at health care industry events in Germany and the UK this spring.
For life sciences investors, the past year has been the busiest period in recent memory, say Goodwin partners Sophie McGrath and David Mardle. But what are the industry's drivers and key investor trends in 2021?